Paper38136389
Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments.
Viscuse PV and 14 others. Cancers (Basel), 2023. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. Papers, record 38136389. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38136389
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30 CA015704 | NCI NIH HHS | United States | P30CA015704 | PubMed |
Source NIH RePORTER
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31040929 | Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. | Oncotarget | 2019 | https://conductscience.org/library/papers/31040929 | PubMed |
| 2 | 35805010 | Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35805010 | PubMed |
| 3 | 24323898 | Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/24323898 | PubMed |
| 4 | 28059768 | SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. | Science | 2017 | https://conductscience.org/library/papers/28059768 | PubMed |
| 5 | 22156612 | Modeling a lethal prostate cancer variant with small-cell carcinoma features. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22156612 | PubMed |
| 6 | 16921051 | Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16921051 | PubMed |
| 7 | 28411207 | Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. | Cancer Discov | 2017 | https://conductscience.org/library/papers/28411207 | PubMed |
| 8 | 33163409 | Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer. | Front Oncol | 2020 | https://conductscience.org/library/papers/33163409 | PubMed |
| 9 | 9815901 | Association of p53 mutations with metastatic prostate cancer. | Clin Cancer Res | 1995 | https://conductscience.org/library/papers/9815901 | PubMed |
| 10 | 33339136 | Neuroendocrine and Aggressive-Variant Prostate Cancer. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33339136 | PubMed |
| 11 | 28059767 | Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. | Science | 2017 | https://conductscience.org/library/papers/28059767 | PubMed |
| 12 | 29985747 | Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29985747 | PubMed |
| 13 | 31515154 | Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/31515154 | PubMed |
| 14 | 29029453 | PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. | Oncotarget | 2017 | https://conductscience.org/library/papers/29029453 | PubMed |
| 15 | 35294956 | Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. | PLoS One | 2022 | https://conductscience.org/library/papers/35294956 | PubMed |
| 16 | 24189654 | Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. | J Mol Diagn | 2014 | https://conductscience.org/library/papers/24189654 | PubMed |
| 17 | 28446506 | Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28446506 | PubMed |
| 18 | 24535589 | Small cell carcinoma of the prostate. | Nat Rev Urol | 2014 | https://conductscience.org/library/papers/24535589 | PubMed |
| 19 | 25225419 | Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. | J Clin Oncol | 2014 | https://conductscience.org/library/papers/25225419 | PubMed |
| 20 | 8023157 | Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. | Science | 1994 | https://conductscience.org/library/papers/8023157 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42220083 | MITF Gain-of-Function Mutation in Metastatic Prostate Cancer: A Rare Finding With Potential Therapeutic Significance. | Cancer Rep (Hoboken) | 2026 | https://conductscience.org/library/papers/42220083 | PubMed |
| 39796175 | The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/39796175 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| PTEN | 5728 | PubTator's text mining | https://conductscience.org/library/genes/5728 | NCBI Gene |
| RB1 | 5925 | PubTator's text mining | https://conductscience.org/library/genes/5925 | NCBI Gene |
| REV1 | 51455 | PubTator's text mining | https://conductscience.org/library/genes/51455 | NCBI Gene |
| TERT | 7015 | PubTator's text mining | https://conductscience.org/library/genes/7015 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38136389
GET https://conductscience.org/api/papers/v1/38136389/references?page=2